GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » UCB SA (WBO:UCB) » Definitions » DeferredTaxAndRevenue

UCB (WBO:UCB) DeferredTaxAndRevenue : €0 Mil (As of Jun. 2024)


View and export this data going back to 2018. Start your Free Trial

What is UCB DeferredTaxAndRevenue?

Deferred Tax And Revenue represents the current portion of obligations, which is a liability that usually would have been paid but is now pas due.

UCB's current deferred tax and revenue for the quarter that ended in Jun. 2024 was €0 Mil.

UCB DeferredTaxAndRevenue Historical Data

The historical data trend for UCB's DeferredTaxAndRevenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

UCB DeferredTaxAndRevenue Chart

UCB Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
DeferredTaxAndRevenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

UCB Semi-Annual Data
Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24
DeferredTaxAndRevenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

UCB DeferredTaxAndRevenue Related Terms

Thank you for viewing the detailed overview of UCB's DeferredTaxAndRevenue provided by GuruFocus.com. Please click on the following links to see related term pages.

UCB Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » UCB SA (WBO:UCB) » Definitions » DeferredTaxAndRevenue
Comparable Companies
XBRU:ARGX XBRU:TUB XBRU:ONWD XBRU:HYL XBRU:ALEMS XBRU:BIOS XBRU:OXUR VRTX REGN ASX:CSL XKRX:207940 ALNY XKRX:068270 BNTX BGNE MRNA SMMT UTHR OCSE:GMAB XKRX:196170
Traded in Other Exchanges
UCBJY:USA UCBJF:USA UCBb:UK 0NZT:UK UNC:Germany UCB:Belgium
Address
Allee de la Recherche, 60, Brussels, BEL, B-1070
Website
https://www.ucb.com
UCB is a Belgium-based biopharma firm focused on the development of novel therapies for the treatment of central nervous system and immunologic diseases. Historically, revenue was derived from allergy medicine Zyrtec and epilepsy drug Keppra, which have both lost patent protection. The firm's key products are Cimzia (immunology), Vimpat (epilepsy), Neupro (Parkinson's disease and restless leg syndrome), Briviact (epilepsy), Bimzelx (psoriasis), Evenity (osteoporosis), Nayzilam (cluster seizures), and Fintepla (Dravet Syndrome and Lennox-Gastaut Syndrome).